Cargando…
KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting
Most small-molecule inhibitors of voltage-gated ion channels display poor subtype specificity because they bind to highly conserved residues located in the channel's central cavity. Using a combined approach of scanning mutagenesis, electrophysiology, chemical ligand modification, chemical cros...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064022/ https://www.ncbi.nlm.nih.gov/pubmed/27731317 http://dx.doi.org/10.1038/ncomms12795 |
_version_ | 1782460070202703872 |
---|---|
author | Wrobel, Eva Rothenberg, Ina Krisp, Christoph Hundt, Franziska Fraenzel, Benjamin Eckey, Karina Linders, Joannes T. M. Gallacher, David J. Towart, Rob Pott, Lutz Pusch, Michael Yang, Tao Roden, Dan M. Kurata, Harley T. Schulze-Bahr, Eric Strutz-Seebohm, Nathalie Wolters, Dirk Seebohm, Guiscard |
author_facet | Wrobel, Eva Rothenberg, Ina Krisp, Christoph Hundt, Franziska Fraenzel, Benjamin Eckey, Karina Linders, Joannes T. M. Gallacher, David J. Towart, Rob Pott, Lutz Pusch, Michael Yang, Tao Roden, Dan M. Kurata, Harley T. Schulze-Bahr, Eric Strutz-Seebohm, Nathalie Wolters, Dirk Seebohm, Guiscard |
author_sort | Wrobel, Eva |
collection | PubMed |
description | Most small-molecule inhibitors of voltage-gated ion channels display poor subtype specificity because they bind to highly conserved residues located in the channel's central cavity. Using a combined approach of scanning mutagenesis, electrophysiology, chemical ligand modification, chemical cross-linking, MS/MS-analyses and molecular modelling, we provide evidence for the binding site for adamantane derivatives and their putative access pathway in Kv7.1/KCNE1 channels. The adamantane compounds, exemplified by JNJ303, are highly potent gating modifiers that bind to fenestrations that become available when KCNE1 accessory subunits are bound to Kv7.1 channels. This mode of regulation by auxiliary subunits may facilitate the future development of potent and highly subtype-specific Kv channel inhibitors. |
format | Online Article Text |
id | pubmed-5064022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50640222016-10-26 KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting Wrobel, Eva Rothenberg, Ina Krisp, Christoph Hundt, Franziska Fraenzel, Benjamin Eckey, Karina Linders, Joannes T. M. Gallacher, David J. Towart, Rob Pott, Lutz Pusch, Michael Yang, Tao Roden, Dan M. Kurata, Harley T. Schulze-Bahr, Eric Strutz-Seebohm, Nathalie Wolters, Dirk Seebohm, Guiscard Nat Commun Article Most small-molecule inhibitors of voltage-gated ion channels display poor subtype specificity because they bind to highly conserved residues located in the channel's central cavity. Using a combined approach of scanning mutagenesis, electrophysiology, chemical ligand modification, chemical cross-linking, MS/MS-analyses and molecular modelling, we provide evidence for the binding site for adamantane derivatives and their putative access pathway in Kv7.1/KCNE1 channels. The adamantane compounds, exemplified by JNJ303, are highly potent gating modifiers that bind to fenestrations that become available when KCNE1 accessory subunits are bound to Kv7.1 channels. This mode of regulation by auxiliary subunits may facilitate the future development of potent and highly subtype-specific Kv channel inhibitors. Nature Publishing Group 2016-10-12 /pmc/articles/PMC5064022/ /pubmed/27731317 http://dx.doi.org/10.1038/ncomms12795 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Wrobel, Eva Rothenberg, Ina Krisp, Christoph Hundt, Franziska Fraenzel, Benjamin Eckey, Karina Linders, Joannes T. M. Gallacher, David J. Towart, Rob Pott, Lutz Pusch, Michael Yang, Tao Roden, Dan M. Kurata, Harley T. Schulze-Bahr, Eric Strutz-Seebohm, Nathalie Wolters, Dirk Seebohm, Guiscard KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting |
title | KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting |
title_full | KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting |
title_fullStr | KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting |
title_full_unstemmed | KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting |
title_short | KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting |
title_sort | kcne1 induces fenestration in the kv7.1/kcne1 channel complex that allows for highly specific pharmacological targeting |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064022/ https://www.ncbi.nlm.nih.gov/pubmed/27731317 http://dx.doi.org/10.1038/ncomms12795 |
work_keys_str_mv | AT wrobeleva kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT rothenbergina kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT krispchristoph kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT hundtfranziska kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT fraenzelbenjamin kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT eckeykarina kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT lindersjoannestm kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT gallacherdavidj kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT towartrob kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT pottlutz kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT puschmichael kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT yangtao kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT rodendanm kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT kurataharleyt kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT schulzebahreric kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT strutzseebohmnathalie kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT woltersdirk kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting AT seebohmguiscard kcne1inducesfenestrationinthekv71kcne1channelcomplexthatallowsforhighlyspecificpharmacologicaltargeting |